

Are you aware of a patient with high-risk primary cSCC?

Consider the SCC-AFTER trial if primary tumour is completely excised (pathology margins $\geq 1\text{mm}$ and BAD guideline surgical margins) and patient has ≥ 2 of following high risk factors (BWH T2b/T3):

- Tumour $\geq 2\text{cm}$ diameter
- Poorly differentiated
- Perineural invasion $\geq 0.1\text{mm}$ diameter
- Tumour invasion beyond fat (and/or thickness $>6\text{mm}$) excluding bone invasion*
- Bone invasion (automatically BWH T3)

*If both factors: invasion beyond subcutaneous fat and thickness $>6\text{mm}$ present it would count as **ONE** prognostic factor for BWH classification

Ensure the patient is discussed at Skin MDT (local or specialist) to confirm eligibility

SCC-AFTER is designed to include groups who are under-served by research – flexible processes including verbal consent are available to facilitate recruitment

Local team contact details:

For the SCC-
AFTER website:

For a full study
summary:



FUNDED BY

NIHR | National Institute for
Health and Care Research

SCC-AFTER Clinic Poster V1.0 30Jan25

SCC-AFTER trial management team:

SCCAfter@cardiff.ac.uk